Advertisement
Screener

OCUGEN, INC. (OCGN) Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate

1.9 / 5 stars · 22/58 Roast Me

OCUGEN, INC. Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate

OCUGEN, INC. (OCGN) reported Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate of 2.57% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.

Discontinued › Notes › Compensation Related Costs

us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate · last filed 2019-03-22

  • OCUGEN, INC. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for the quarter ending 2018-09-30 was 1.97%, a 45.93% increase year-over-year.
  • OCUGEN, INC. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for the quarter ending 2018-06-30 was 1.97%, a 45.93% increase year-over-year.
  • OCUGEN, INC. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for the quarter ending 2018-03-31 was 1.97%, a 84.11% increase year-over-year.
  • OCUGEN, INC. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for the quarter ending 2017-09-30 was 1.35%, a 11.76% decline year-over-year.
  • OCUGEN, INC. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for fiscal 2018 was 2.57%, a 99.22% increase from fiscal 2017.
  • OCUGEN, INC. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for fiscal 2017 was 1.29%, a 17.83% decline from fiscal 2016.
  • OCUGEN, INC. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for fiscal 2016 was 1.57%, a 12.29% decline from fiscal 2015.
  • OCUGEN, INC. share-based goods and nonemployee services transaction, valuation method, risk free interest rate for fiscal 2015 was 1.79%, a 101.12% increase from fiscal 2014.
Period endShare-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate 3 monthShare-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate 6 monthShare-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate 9 monthShare-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate 12 month
2018-12-312.57%
10-K · filed 2019-03-22
2018-09-301.97%
10-Q · filed 2018-11-08
1.97%
10-Q · filed 2018-11-08
2018-06-301.97%
10-Q · filed 2018-08-09
1.97%
10-Q · filed 2018-08-09
2018-03-311.97%
10-Q · filed 2018-05-10
2017-12-311.29%
10-K · filed 2019-03-22
2017-09-301.35%
10-Q · filed 2018-11-08
1.28%
10-Q · filed 2018-11-08
2017-06-301.35%
10-Q · filed 2018-08-09
1.14%
10-Q · filed 2018-08-09
2017-03-311.07%
10-Q · filed 2018-05-10
2016-12-311.57%
10-K · filed 2018-03-15
2016-09-301.53%
10-Q · filed 2017-11-09
1.59%
10-Q · filed 2017-11-09
2016-06-301.56%
10-Q · filed 2017-08-10
1.61%
10-Q · filed 2017-08-10
2016-03-311.66%
10-Q · filed 2017-05-11
2015-12-311.79%
10-K · filed 2017-03-16
2015-09-301.79%
10-Q · filed 2016-11-10
1.66%
10-Q · filed 2016-11-10
2015-06-302.64%
10-Q · filed 2016-08-11
1.60%
10-Q · filed 2016-08-11
2015-03-310.56%
10-Q · filed 2016-05-12
2014-12-310.89%
10-K · filed 2016-03-10
2014-09-300.95%
10-Q · filed 2015-11-12
1.07%
10-Q · filed 2015-11-12
2014-06-300.88%
10-Q · filed 2015-08-12
0.68%
10-Q · filed 2015-08-12
2014-03-310.57%
10-Q · filed 2015-05-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
AGENUS INC (AGEN)United States$0.383B1.41
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Surrozen, Inc./DE (SRZN)United States$0.395B